(Q34727571)

English

The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations (English)

1 reference

Europe PubMed Central

4 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

coronary artery disease

1 reference

based on heuristic

inferred from title

author name string

Frank M Sacks

1

1 reference

Europe PubMed Central

4 August 2017

Expert Group on HDL Cholesterol

2

1 reference

Europe PubMed Central

4 August 2017

language of work or name

0 references

publication date

1 July 2002

1 reference

Europe PubMed Central

4 August 2017

American Journal of Cardiology

1 reference

Europe PubMed Central

4 August 2017

90

1 reference

Europe PubMed Central

4 August 2017

2

1 reference

Europe PubMed Central

4 August 2017

139-143

1 reference

Europe PubMed Central

4 August 2017

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

Hypertriglyceridemia, insulin resistance, and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examination Surveys.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

Range of serum cholesterol values in the population developing coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

High-monounsaturated-fat diets for patients with diabetes mellitus: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

The role of fibric acids in atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

Mechanism of action of niacin on lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902436-0

7 January 2021

Identifiers

10.1016/S0002-9149(02)02436-0

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34727571&oldid=1629890732"